^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Non-Hodgkin’s Lymphoma
    Drug:carmustine (DNA synthesis inhibitor, Alkylating agent)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    FDA
    Published date:
    05/16/2022
    Excerpt:
    Carmustine for Injection is a nitrosourea indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in the following...Relapsed or refractory non-Hodgkin's lymphomas in combination with other approved drugs...
    Secondary therapy:
    Chemotherapy
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    European Medicines Agency
    Published date:
    07/18/2018
    Excerpt:
    Carmustine is effective in the following malignant neoplasms as a single agent or in combination with other antineoplastic agents and/or other therapeutic measures (radiotherapy, surgery):…Secondary therapy in non-Hodgkin’s lymphoma and Hodgkin’s disease...